Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 216-225

  Vidal, Liat ^a,b   Gafter Gvili, Anat ^a,b   Salles, Gilles ^c   Bousseta, Sami ^d   Oberman, Bernice ^e   Rubin, Carmit ^e   van Oers, Marinus H J ^f   Fortpied, Catherine ^g   Ghielmini, Michele ^h,i   Pettengell, Ruth ^j   Witzens Harig, Mathias ^k   Dreger, Peter ^l   Vitolo, Umberto ^m   Gomes da Silva, Maria ⁿ   Evangelista, Andrea ^m   Li, Hailun ^o   Freedman, Laurence ^e   Habermann, Thomas M ^p   Shpilberg, Ofer ^q  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITÉ LYON 1   (France)

^d Biostatistics Department   (France)

^e GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g EORTC DATA CENTER   (Belgium)

^h ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l EBMT Lymphoma Working Party   (France)

^m CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

ⁿ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^o Dana Farber Cancer Center   (United States)

^p MAYO CLINIC   (United States)

^q ASSUTA MEDICAL CENTER   (Israel)

more..

Author keywords

Follicular lymphoma; Maintenance; Meta analysis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADVERSE OUTCOME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DRUG SAFETY; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; INFECTION RISK; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; META ANALYSIS; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INDUCTION CHEMOTHERAPY; INFECTION; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITUXIMAB; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 85015783936     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.021     Document Type: Article

References (19)

1. [1] Vidal, L., Gafter-Gvili, A., Salles, G., et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 103 (2011), 1799–1806.
2. [2] Ardeshna, K.M., Qian, W., Smith, P., et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. [Internet]. Lancet Oncol 15 (2014), 424–435 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24602760.
3. [3] Forstpointner, R., Unterhalt, M., Dreyling, M., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular [Internet]. Blood 108 (2006), 4003–4008 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16946304.
4. [4] Ghielmini, M., Schmitz, S.-F.H., Cogliatti, S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. [Internet]. Blood 103 (2004), 4416–4423 Available from: http://www.ncbi.nlm.nih.gov/pubmed/14976046.
5. [5] Hainsworth, J.D., Litchy, S., Shaffer, D.W., et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. [Internet]. J Clin Oncol 23 (2005), 1088–1095 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/15657401.
6. [6] Martinelli, G., Schmitz, S.F.H., Utiger, U., et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28 (2010), 4480–4484.
7. [7] Pettengell, R., Schmitz, N., Gisselbrecht, C., et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. [Internet]. J Clin Oncol 31 (2013), 1624–1630 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23547078.
8. [8] Salles, G., Seymour, J.F., Offner, F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 (2011), 42–51.
9. [9] Van Oers, M.H.J., Van Glabbeke, M., Giurgea, L., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28 (2010), 2853–2858.
10. [10] Ghielmini, M., Vitolo, U., Kimby, E., et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). [Internet]. Ann Oncol 24 (2013), 561–576 [cited 2015 Jul 12] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23175624.
11. [11] Vitolo, U., Ladetto, M., Boccomini, C., et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Lin [Internet]. J Clin Oncol 31 (2013), 3351–3359 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23960180.
12. [12] Witzens-Harig, M., Benner, A., McClanahan, F., et al. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. [Internet]. Br J Haematol 171 (2015), 710–719 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26449739.
13. [13] Kahl, B.S., Hong, F., Williams, M.E., et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. [Internet]. J Clin Oncol 32 (2014), 3096–3102 [cited 2016 Feb 24] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25154829.
14. [14] Higgins, J.P.T., Altman, D.G., Higgins 2011 Higgins JPT. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Green, S., (eds.) Cochrane Handbook for systematic reviews of interventions, 2011, 2011.
15. [15] Hochster, H., Weller, E., Gascoyne, R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 27 (2009), 1607–1614.
16. [16] Altman, D.G., Andersen, P.K., Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319 (1999), 1492–1495.
17. [17] Trotman, J., Luminari, S., Boussetta, S., et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. [Internet]. Lancet Haematol 1 (2014), e17–e27 [cited 2016 May 31] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27030064.
18. [18] Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines|ESMO [Internet][cited 2016 Feb 24] Available from: http://www.esmo.org/Guidelines/Haematological-Malignancies/Newly-Diagnosed-and-Relapsed-Follicular-Lymphoma.
19. [19] Rummel, M.J., Niederle, N., Maschmeyer, G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381 (2013), 1203–1210.